Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

@article{Berenson2006PhaseIT,
  title={Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.},
  author={James R Berenson and Hank H. Yang and Karen Sadler and Supol G Jarutirasarn and Robert A. Vescio and Russell Mapes and Matthew B. Purner and Shi-pyng Lee and Joanna N. Wilson and Blake Morrison and Julian Adams and David P. Schenkein and Regina Swift},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 6},
  pages={937-44}
}
PURPOSE Bortezomib has shown synergy with melphalan in preclinical models. We assessed the safety, tolerability, and response rate in a dose-escalation study of this combination for relapsed or refractory multiple myeloma patients. METHODS Bortezomib was administered from 0.7 to 1.0 mg/m(2) on days 1, 4, 8, and 11 of a 28-day cycle for up to eight cycles. Oral melphalan was administered in escalating doses from 0.025 to 0.25 mg/kg on days 1 to 4. RESULTS Thirty-five patients with relapsed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

A phase 2 study of two doses of bortezomib in Berenson et al 942 JOURNAL OF CLINICAL ONCOLOGY Copyright © 2006 by the American Society of Clinical Oncology

  • S Jagannath, B Barlogie, J Berenson
  • All rights reserved. Information downloaded from…
  • 2006
Highly Influential
5 Excerpts

A phase I/II national, multi-center, open-label study of Velcade plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients

  • MV Mateos, J Blade, JD Mediavilla
  • Haematologica 90:149,
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…